arrow
J

José Moltó

Hospital Universitari Germans Trias i Pujol
H指数:35
被引数:4,196

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First-line dolutegravir/lamivudine in HIV-1 infection: lymph node penetration and reservoir decline in a randomized open-label clinical trial

HIV-1感染中一线多替拉韦/拉米夫定治疗:一项随机开放标签临床试验中的淋巴结渗透和病毒库下降

2026-10-020
OA
Immunogenicity, reactogenicity and safety to assess booster vaccinations with BNT162b2 or double-dose mRNA-1273 in adults ≥75 years (EU-COVAT-1-AGED) – final report
2026-02-060
OAAI
Predictors of virological outcomes after analytical interruption of antiretroviral therapy and HTI vaccination in early treated people with HIV-1._

早期接受治疗的HIV-1感染者中,抗病毒治疗分析性中断和HTI疫苗接种后病毒学结局的预测因素。

2025-12-080
OAAI
Strategies to Minimize Time From HIV Acquisition to ART Initiation: The Barcelona Early-cART Program

从HIV感染到启动ART治疗的时间最小化策略:巴塞罗那早期ART项目

2025-09-011
OAAI
Interactions between gut microbiota; plasma metabolome and brain function in the setting of a HIV cure trial

肠道微生物组、血浆代谢组与脑功能在HIV治愈试验背景下的相互作用

2025-08-200
OA
Safety and immunogenicity of PHH-1V booster against SARS-CoV-2 variants, including omicron subvariants: Results from a phase IIb open-label extension study

PHH-1V加强针针对SARS-CoV-2变种(包括奥密克戎亚变种)的安全性与免疫原性:一项IIb期开放标签扩展研究的结果

2025-04-300
OAAI
Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial

HTI疫苗联合TLR7激动剂在早期治疗HIV-1感染中的安全性、免疫原性及对病毒反弹的影响:一项随机、安慰剂对照的2a期试验

2025-03-040
OA
Impact of Dolutegravir Plus Lamivudine as First-line Antiretroviral Treatment on the Human Immunodeficiency Virus Type 1 Reservoir and Inflammatory Markers in Peripheral Blood

度鲁特韦联合拉米夫定一线抗逆转录病毒治疗对外周血人类免疫缺陷病病毒1型储库和炎症标志物的影响

2024-10-280
PRE
Omicron XBB.1.16-Adapted Vaccine for COVID-19: Interim Immunogenicity and Safety Clinical Trial Results

Omicron XBB.1.16-适用于新型冠状病毒肺炎的疫苗: 临时免疫原性和安全性临床试验结果

2024-07-250
OAAI
A Randomized Trial of Dolutegravir Plus Darunavir/Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes
2023-10-313
OAAI
Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial

基于蛋白质的PHH-1V与BNT162b2作为异源SARS-CoV-2加强疫苗在成人新型冠状病毒肺炎疫苗中的安全性和免疫原性比较: 多中心,随机,双盲,非劣效性IIb期试验

2023-05-0116
OA
Rapid artificial intelligence solutions in a pandemic-The COVID-19-20 Lung CT Lesion Segmentation Challenge
2022-11-0124
OA
Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial

HTI疫苗在早期治疗的HIV-1感染中的安全性,免疫原性和对病毒反弹的影响: 一项随机,安慰剂对照的1期试验

2022-10-2733
OA
Limited Humoral and Specific T-Cell Responses After SARS-CoV-2 Vaccination in PWH With Poor Immune Reconstitution
2022-10-0624
OA
Lessons from an international trial evaluating vaccination strategies for recovered inpatients with COVID-19 (VATICO)
MED
IF11.8
2022-08-012
OAAI